Prostate Cancer Biomarker Enrichment and Treatment Selection

NCT03385655 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

NETWORK

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Adavosertib
DRUG: Savolitinib
DRUG: Darolutamide
DRUG: CFI-400945
DRUG: Ipatasertib
DRUG: Durvalumab and Tremelimumab
DRUG: Carboplatin

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]